Episode 3: Hope Is More Powerful Than Fear, with Suzanne Morgan

Final transcript, lightly edited for readability. Timestamps match the published episode. The views expressed by guests are their own.

00:08 Patrick Coyle: I am Patrick Coyle, and this is Patients + Profitability. I created this show because I spent my career seeing what happens when patient access and healthcare economics become disconnected. Most organizations manage those separately. I believe they’re actually the same conversation. When patients struggle to access therapy, businesses struggle too. My work is helping organizations connect patient outcomes with financial sustainability. And every episode, I sit down with one person who has lived both halves of that sentence. Today, that person is Suzanne Morgan. Suzanne, rather than read a bio at you, please tell me all about you and my audience.

00:46 Suzanne Morgan: Thank you. So, Suzanne Morgan, I have been in the pharmaceutical industry for 33 years now. I originally got into it. I had an uncle that worked for Merck Sharp & Dohme. So, growing up, I always saw these little models of feet and hands and elbows, and I was like, “This is fascinating. So, when I was in college, I thought I wanted to be a doctor, so I was premed. But by the time I graduated, I was like, “Let me try to do what my uncle does. So, got into pharma right out of college. Spent the first 10 years in sales, then the next 10 probably jumping around in all kinds of roles between training, development, management, reimbursement, and then the last decade has been really focused on rare disease, specifically market access and patient services.

01:25 So I feel like I have a good, well-rounded view of everything on the commercial side of pharma, and so it kind of informs my decisions.

01:40 Patrick Coyle: And I love it because we just talked about this incredibly amazing, diverse career you’ve had, and you didn’t even talk about this next segment that you’ve been working on, which has been phenomenal to watch unfold in your thought leadership. Before we go any further, Suzanne Morgan’s feelings and opinions are just hers and not hers of not of the organization. So, 30 years, big pharma, then specialty, rare disease, ultra rare now. Every move smaller in headcount, and sometimes that’s hard to explain to people why you do that. So, what moved you in that direction?

02:14 Suzanne Morgan: I think that as I progressed through my career, I would go from kind of role to role. When I was at Centocor J&J, they were growing, and so I had the opportunity to jump into several roles to start to figure out what I liked and maybe what I was good at. And so I think as my career progressed, I was able to fine tune more and more what I really like to do, and I just found that the big pharma route wasn’t for me. That I really enjoy the small startup biotech, where many hats really go into roles where you may not even know how to do it. You just know you’re going to have to figure out how to do it and pull in the resources.

02:52 And for whatever reason, that speaks to my… I don’t know if it’s a strength, but I’m not afraid to do that, and so I think that’s why it went big pharma and now smaller and smaller. Because now I really feel like I’m hitting my stride and I’m in the right niche.

03:12 Patrick Coyle: And I don’t know if this is what did it for you, but in my career, I found that sometimes as you move up and you’re in these bigger organizations is harder and harder to feel that impact you’re making more immediately, where you know it’s being felt on a longer period of time, but you don’t always see those people in the room. Did you have any part of that also?

03:34 Suzanne Morgan: Oh, for sure. When I started out, I was in bigger disease states like rheumatoid arthritis and psoriasis, and although you have a feeling for these patients because you may have seen interview or whatever, it really was not until I got into rare disease with Duchenne muscular dystrophy that I specifically felt connected to these patients.

03:49 My first week on the job, I went to PPMD, which is one of the main DMD advocacy groups to train myself on the disease state, and in that room was where I met other advocates, other patients, other people, and I was like certainly connected immediately to these people, and it really informed my daily motivation because I had seen what these families and mothers and children have gone through, and so I felt so connected to make sure every day I’m working hard on their behalf and just keeping them in mind in everything I do. So that was probably the first time in my career where I was like, “Oh, I’m locked in. This is it. This is exactly where I always want to be. I always want to be with rare disease, so.

04:42 Patrick Coyle: I think it’s amazing. There was a period in my career where I got to meet a patient that, because of a program and affordability, that I met that patient. They told me that they were able to get on therapy, stay on therapy longer, would have never been able to likely. Afford it and living much longer than expected, and it changes you when you meet these people. And we spend our whole careers being told you can’t meet them, you can’t ID them, you can’t know them. And it’s the opposite of what I hear from you and what tugged me is you want to get them, you want to get to know them more, want to help them appropriately. Tell me a little bit about is there one patient without obviously naming them that did that for you in your career?

05:29 Suzanne Morgan: Yeah, I think what has been good for me is I’ve always been on the patient services side of the business, or at least the last few roles I’ve been in. So with that comes the ability to know PHI, and really the ability to know the patients. And I remember getting to know this one mother. And when she first got the diagnosis of her son at the age of four, it was a death sentence at that time. There weren’t any medicines out on the market, and she just started praying and trying to figure out what to do, and I just heard her story how she started as a school teacher, and before she knew it, she’s leading advocacy organizations and being on the Hill and running things in her state.

06:10 And I just was like, it’s amazing how this stuff leads you to a role and a job and a purpose that you never knew you were designed for, but you literally just took the next step, even though that next step might not have been really where you wanted to be or what you wanted to be.

06:31 But I think her strength also filtered down to her son because her son was also that kind of kid that knew that eventually he would die younger than most people with no disease, but he wanted to make an impact every day while he’s there, and so that really moves you to make sure that you are working really hard and never feeling sorry for yourself, putting yourself in their position and knowing that they didn’t ask for that, but my Lord, they really made the best out of it that they could.

07:02 Patrick Coyle: You just hit on something that I don’t think somehow I realize that person, that patient, that mother, that child that you get to know that eventually won’t be there no matter what you do, right? Because you’re just helping them to live life better, live life longer, and in the end, unfortunately, until we have curative intent in that area, there’s nothing you can do to stop it. That’s hard.

07:33 Suzanne Morgan: It’s really hard, and you live it every day. And I think that’s why you’ll see rare disease families and advocates march up to Capitol Hill and be at these adcoms and be on the hill and just scream from the highest, the top of the mountain, because they just want something. They’re willing to take that risk. Maybe the drug doesn’t work. Maybe the drug is toxic. But they’re willing to take that risk because what’s the alternative? The hope is more powerful than the fear, right? So I feel for all these families, and they’re really my heroes. They really are.

08:10 Patrick Coyle: All the hope is more powerful than the fear. That is amazing because that’s what you’re, you and everybody else, whether you’re on the provider side, whether you’re on the pharmaceutical side, whether you’re a scientist, whether you’re a patient access, you’re an advocacy, every caregiver, we’re all in it for the same reasons. And as you’ve gone through your career, you told me last time we talked that you still felt this deep connection and responsibility for those patients you’ve helped. Maybe tell me.

08:46 Suzanne Morgan: Every day. For example, I run a patient services program, and we have patients that don’t qualify or can’t get to the drug. That that deeply hurts. My organization will think about how they can possibly support these patients within the guides of the law? You have really strict OIG guidance on these programs. You don’t ever want to get in trouble, but literally we would be as generous as we could. So it’s interesting. I was reading a Substack this morning, and it was a father that chronicled his journey with his daughter with cancer, and he was really upset with patient access programs. Actually, and I was like, “Gosh!

09:18 And so he described what it was like that when the doctor prescribed the medicine, they knew it would be denied, and then he heard that he was going to have to go through two denials to get to free drug, and to him that was a service, and that was painful because as the first denial came through, the appeal went through, and he was watching his daughter die on the couch, and I’m thinking to myself, I’m the person on that other side that has to go. By these guidelines, that we have to have those denials, we have to have that in order to be able to provide that. And I thought, I don’t know what the company was, I don’t know what the drug was, but I do know that we have patient engagement liaisons that would have been speaking with that father that whole time.

10:12 And trust me, they have the heaviest job. They hear these stories, and I just thought, what a injustice and a disservice for that poor father because he couldn’t or didn’t know to talk to company or the engagement liaison that could have been saying, stick with it. This I know this is tough. This is where we’re at right now. It was heartbreaking, and I thought that’s what I never want to have happen. Is someone in my program feel like I don’t care, or I’m just going through the motions, or this is a circus? I think anyone on my side of the business want to get that drug to that patient as soon as possible, but we have to follow certain laws and guidelines, and it keeps all of us safe, right?

11:01 Patrick Coyle: As you talk about that, I’m reminded that this podcast, Patients + Profitability, was born out of my philosophy working in pharma. And the first thing I did was not let me go start a podcast. The first thing I did was start talking about all the different places and what I call the 10 Exits of Therapy™. There’s probably realistically 12 or 13 or 14, but for any brand, there’s 10 places that just getting on, getting treated can fall off. And I make it my purpose to speak to consumers because consumers are all patients to try and understand all those barriers that they put up, because my wish and my dream is that one patient learns how to improve that journey, not from a brand side, right? But just from a what does an appeal mean? What does a reject code 75 mean?

11:51 I always go back to that because that’s not just a number. That is the difference between an extension of life, quality of life, or maybe even life itself, and so that number becomes everything. And you’ve worked in big pharma companies. I’ve worked in big pharma companies. The chances of programs changing and evolving fast enough keep up with the craziness and that goes on in people trying to push their own profits at their extent back at the cost of the patient at the cost of the pharma company, I think in 2026 and beyond it’s time to break those all down. I don’t.

12:25 What are your feeling your feelings about some of those things like that you know not now but have done or can do and what can we all do to raise the awareness so that, again, outside of patient support programs or patient assistance programs, what can be done to help that father never have to write that article?

12:53 Suzanne Morgan: In previous program, we were so dialed into these patients and what was happening that when we knew a denial letter was coming. We warned them. We would say, “You’re going to get a denial letter. It’s going to say this. This is what we’re going to do. So, it’s so important in these patient services program to be so lock and step with your patients. And we know what happens. So, if we can get ahead of it and protect these patients, or at least explain this is what why it’s happened, but it’s really hard. My program, this one and the other one, we don’t have a lot of patients. We have a few, but when you are managing huge programs, that maybe it’s not a rare disease.

13:33 That’s why I don’t know what that father’s daughter had, but it would be really hard to reach out to warn them, right? Like, hey, just ignore this letter; it’s coming. And that’s also where I get really worried. I had someone reach out to me on LinkedIn about AI in patient services, and I said, “Don’t even ask me about it on rare disease. I would be mortified if I had AI reach out to any of my patients. Maybe big pharma. Just literally, if you have the program and the capabilities, just make sure your engagement leads or your field reimbursement managers or whoever are so locked into those patients at all times that we don’t let that slip. And that might be pie in the sky, but that’s always the goal.

14:18 Patrick Coyle: You just carved out the perfect role for human intelligence going forward, right? Especially around the patient, the AI is here. The vendors, the solutionists around a brand journey are deploying it like crazy right now. I see it working with all them, and I go and I help brands and take a look, and all of a sudden you realize that the AI is compounding. If you have five different vendors, that’s five different potential AI programs. So the human becomes the most important part, and then you set it. You’re never going to want AI to talk to a patient, but but the AI is in the process. So we have to know it’s there and govern it. I see a huge opportunity for that.

14:59 Suzanne Morgan: And I’m. I’m an AI. I’m bullish on AI. I love it, but I love it for drug discovery for rare disease. I love it for helping physicians sort through mega pieces of information for a rare disease. I love it for that. But when it comes down to delivering hard news or delivering anything that needs compassion and empathy, I’m anti.

15:18 Patrick Coyle: And I think there’s something too that you talked about in how do we both stay with a manufacturer past our time serving that manufacturer, serving those patients? How do we stay on with that? And the other thing is the service doesn’t end, right? And until the end, and then beyond, because that caregiver has to go on. And maybe tell me your thoughts about that, because I’ve often thought about how do we just continue to help the patients past the therapy ending?

15:46 Suzanne Morgan: You mean if the patient their prescription ended? I know for our program we just keep we check in every few months just to make sure everyone’s okay, so we never leave them. And I know that my engagement lead, she’s still friends with families from the old disease state that she was working in. So, I think you become so connected that it’s a travesty if you can’t connect these patients because you really become part of their family, part of their livelihood. You are a lifeline for them. I think just be able to be human and stepping outside of your job and your role and just reaching back out and making sure how people are doing, long as that’s right compliant, which you know, but there’s also the human side of things too.

16:25 Patrick Coyle: Yeah, I would love to see, and I know like some companies out there do it better than others, but I would love to. What I was thinking about was not just beyond where the therapy is ended, and hopefully the patient’s in a much better place, but the unfortunate ones we talked about earlier where there’s only one ending for a patient, and we know that, and the therapy ends. But then, how do there’s got to be a way we can continue our commitment to helping them and supporting them on the healing part.

16:54 Suzanne Morgan: That’s a great point, even the grieving part because it happens. You’ll hear all the time within your job that oh that patient passed away, and I guess you’re right. We don’t really, as an industry, have a what’s next. We don’t have the grieving or the resources that would help that mother, father, family where to go. That’s a great idea. Thinking of that too.

17:18 Patrick Coyle: Yeah, this is a call to action. I think for every specialty pharmacy out there, these products that are supporting the patients and to the manufacturers of keep the program going longer and provide that support that they need and that close touch. When you, I think there’s something we talked about last time, and you’re working a lot throughout your career with the advocates, caregivers about how you’ve worked with caregivers and how you help them find their voice, and they become advocates. what that process for you gets to look like when you see that happening, it’s got to be beautiful.

17:58 Suzanne Morgan: I think in the roles that I’ve had, I’ve gotten to meet the mothers that have stood up to be advocates, and I think that maybe some of these-I say mothers, and it’s not fair to the fathers, but it’s all the mothers. They’ll see other mothers and then start to really dig in and find their voice too. So I think that as they fight for their child and as they go through the emotions, there’s something that just becomes unleashed where they just start to become someone they never thought they could be, and it feels good.

18:26 And so to be able to express that, so that is a beautiful thing, and it’s been really cool to see a lot of these families become ambassadors or whatever that now they want to help other people because they know what they’ve been through, and that’s kind of what makes life and relationships worthwhile, right? When you can really start to share and give back and help others.

18:50 Patrick Coyle: And maybe there’s a huge opportunity for them to become brand ambassadors for what is going to be eventual, and they’re going to. I did some work with hospice in one of my roles in a nonprofit, and it was really eye-opening, right? Because you’re with them till the very end. But I think there is a chance that, again, back to the other thing that pharma out there can really dig in and bring that advocacy back full circle of end of life to beginning of the journey for somebody else. And one of the things that stuck out to me last time we talked about was, like you said, you’re holding on to that patient and that journey, even though the manufacturer changed for you. And I think you’ve done something fascinating when that’s happened throughout those transitions.

19:30 You started speaking publicly and under your own name during a period in between jobs or doing consulting, we touched on in the beginning. Tell me all about what you’re the great work you’re doing out there.

19:50 Suzanne Morgan: When I lost my job, it was the first time in 30 years I’d ever lost a job, and I was not prepared to know what to. And I am an introvert, kind of by nature, and so I never really looked at social media or networking. It didn’t seem natural to me, and I was not good at it. But I realized that if I want to start finding other roles and other jobs, I needed to be more active on social media, and so I went through a period of prayer because I was one of those which I think more often than not, people are like, I’m scared of social media. I don’t want to be on social media, and I was that person for sure. But I ended up just getting to posting on LinkedIn every day for 365 days and see what would happen.

20:31 And so as I started posting, it was cathartic to kind of talk about my journey. And then I realized you’d get some comments here and there, and that really spoke to me. Suzanne, thanks for sharing that. That and I realized I had perspective that were helping people. And then as I then got a job, and then as my role, as I am in now, executive director, I have to read a lot of information. I have to process a lot of information, and so I thought, let me help other people process information. So now I post a few days a week on what’s new in rare disease, what’s new in rare disease and AI, and then a couple posts a week.

21:08 One on my faith and how that is in the workplace, and then one on something I learned in leadership that week, whether it’s good or bad. So I think that journey has just evolved from someone that was so scared of social media into someone I really actually enjoy it now, and really don’t get a lot of negative comments. And when I do, you just that’s okay. I feel like whatever I put out, I’m really trying to help someone, educate someone, let them know what’s out there. And I think that brought me a nice community within LinkedIn. Share my thoughts and things that I’ve been through.

21:41 Patrick Coyle: Going through your work out there, it’s amazing. I think you’re raising so much awareness in the broad community of of the people we deal with. Right, LinkedIn isn’t just pharma professionals, but there’s a lot of other people out there. But you’re raising awareness of AI and clinical trials and responsibility there, and also for patients and how we advocate more. I just think it’s fascinating because the more you do that, the more we’re helping. Just imagine one follower sees something that they didn’t know or could help. So I just think it’s fascinating. I’d love to see even more of that.

22:17 Suzanne Morgan: There’s something I do periodically called Beginner’s Guide To, and then I usually try to choose a rare disease that I’ve seen in the news that week, and I have had comments on those because it might be Angelman syndrome, or one week it was something else. And I’ll have someone reach out and be like, “Oh my gosh, my so and so has that, or “I think I have that, and I’m like, “I’m not a doctor, but it just literally is the ability to raise awareness, and you just hope that algorithm takes that, and algorithm just spews whatever it can. But that’s how you raise awareness to this stuff. Is no one thinks about rare disease because it’s rare, but you let one person know, then that’s kind of how it you start to educate others on that.

22:56 Patrick Coyle: Just because it’s rare doesn’t mean that disease awareness has to be low.

23:00 Suzanne Morgan: Exactly. Exactly.

23:02 Patrick Coyle: And I love it. And I think the more and more you can do that, and just picking a rare disease and raising awareness just increases the likelihood that it’s going to be diagnosed properly or tested for properly. And hopefully, there’s a treatment for it if there’s not already. My hope is that there’s even more advocates that have this huge book of knowledge from your career, just doing totally different things. Not everybody could jump around between roles one company because you just you learn you take that with you. So I think it’s a great keep bringing.

23:36 Suzanne Morgan: Thank you. I appreciate that. It’s become fun, and I think too the issue with a lot of rare diseases is they mimic common illnesses, and so they get what’s called the diagnostic journey. It’s why it takes five to seven years for these families and patients to get a diagnosis. So if you can alert them on something that they’re like, wait, I have that. Please don’t go to their doctor, right? I’m not here to diagnose, but maybe that’s just an awareness, or maybe I should ask them if they’ve thought of that or heard of that. Yeah.

24:05 Patrick Coyle: Some of the disease states that I know more about than others through the course of talking about what I do and people asking family, friends, they’ve taken me in a certain direction. And just like you, what I’ve found now is that I have more and more people coming to me for a very specific thing. One happens to be prostate cancer. It’s an incredibly complicated journey because there’s so many different types of treatment options out there. I have unfortunately family and then friends too, or friends of friends that come to me and say, “What do I do? I say, “Listen, I’m not qualified you for helping, but I can tell you the type of journey I think you’re going to go through.

24:41 I interpret where you are, then hopefully help them come to their decision of where they want to go in their journey with their provider together. But that’s been incredibly rewarding. So if we talk about because the show is Patients + Profitability, and I think we’ve already covered you do the right thing for patients. You find a way to help it be sustainable for innovation, like we talked about. But something I keep coming back to is an emerging pharma success. It’s not measurable until you have the first product launch, and then what are we doing? We’re hyper measuring it. But what does it do for an organization while you’re going through that process as you launch, and the whole weight of the investment to date is on the team. What does that look like? Without naming a company.

25:31 Suzanne Morgan: It’s definitely very stressful, but it’s also very exhilarating because if you don’t know anything about the disease state, you are learning and you are trying to figure out like what kind of doctors do these patients see? So a lot of that pre-launch excitement is you’re just in learning phase, learning about disease, or like on my side of the business, what are the payers going to say? What are the payers going to think? So you hold a lot of ad boards to get a feel for what they might be thinking, and if they can inform you what they might be thinking. Then maybe you can get the information they need to bring that to market. A lot of companies are on pins and needles waiting because in 2025 there were several companies that got CRLs that were not expecting them, and it’s devastating.

26:12 These become your little babies. You love your product. You love everything about it, and then it’s very devastating if that doesn’t get approved. But excitement, though, is also worth it because when it finally does get approved, you’re ecstatic, and then all of a sudden it’s now we really have to go right. So then you hope that all of your strategies and everything else work, and that you were correct in what you saw as the strategy that should work.

26:40 Patrick Coyle: Yeah, and I think our listening audience outside of the industry, I don’t think they can understand that the success at that point in time is out of your hands. Success defined broadly, just to say in launch or approval by the FDA is out of your hands. It’s in God’s hands. It’s been a lot of things, a lot of people touching it until then, and it’s in God’s hand, and sometimes it’s not meant to be. It just was we thought the science was going to do something, and it didn’t. It we’re testing the hypothesis out, And then sometimes it does. When it does, that’s a whole different ball game because now you have to recoup sometimes $1.8 billion on average for a trial. But oh yeah, by the way, if it’s your first one, you could have had three, right?

27:20 Now all of a sudden we’re pushing on five and a half million dollars. So that is incredible cross to bear for an emerging biopharma, and I think I hope that people understand and look at things different because what do you see out there? People read the news of this bad behavior and that bad behavior, or this pricing decision. I don’t think they really understand the tremendous amount of work that goes into that.

27:50 Suzanne Morgan: Decades, people have spent their life on this one mission in in the lab, or in the trial, or looking at the trial, or looking at the statistics, or wondering that they put the right endpoint in there, or watching the first readout and maybe being disappointed with the first readout, and how do we reassess this? Especially in rare disease, if you don’t know a lot about that disease to start with, your clinical trial can be guess. I think we should measure six-minute walk test. Maybe that’s a great endpoint, but you don’t know until the data starts coming back. So it really is just you.

28:20 Just hope that you have the smartest of the the smartest and the best of the best that are creating all of this and guessing and working with your KOLs, your physicians that know about the disease the best that they can help inform. And so it really is enlightening the things that go into the preclinical, like me being on commercial, I was always like, “Pass me football, I’m ready to take it. But as you get into smaller companies, you’re exposed more to what happens on the R&D side, and it’s fascinating. It’s brilliant, and you have these scientists that are constantly thinking about it and thinking about the trial and years and decades and millions of dollars, and nobody’s trying to get rich. They just want to bring this product to market.

29:05 You became so focused on these patients and the KOLs, the doctors that treat them, and learning. And it really is. I wish that people could see that too. Versus, I’ve made a billion dollars this quarter. There’s a lot that goes on that are just really good human beings trying to do the right thing, and just love their jobs.

29:25 Patrick Coyle: Thank you for that. And I think on the pharma side, for people that part of the big machine, that are employees that are pulling this huge weight together, and may never ever see R&D or see that KOL before they were that, and they just had patients in your trial. And guess what? They’re really hard to find.

29:46 Suzanne Morgan: For sure.

29:47 Patrick Coyle: So you get approval. Some of those physicians, those providers have the experience that nobody else does, and then hopefully they can move toward that proper diagnosis and treatment. So one of the things that. Come up over and over again on the shows is faith, and it’s very interesting because it’s different people, different backgrounds, different religions, different countries. So not any of that individuals aside, each of us has is the practice of our own business and has a higher purpose in doing good. At the end of the day, you’ve written that your leadership comes from a quiet strength. It comes from faith. Can you tell me about that?

30:27 Suzanne Morgan: Yeah, I was raised very strong Christian women, and then I think that once you’re kind of raised up in it, it’s kind of up to you whether or not you want to take it right. And so it was probably in my mid 30s where I was like, my life isn’t quite right. I’m not happy. I should be happy on the outside. It seems like you have everything, but something’s missing. And so, I really, in my 30s, did a really big deep dive into my faith. And I studied a lot of other faiths too, just to make sure the one that I had been raised on was maybe the one that I should be raised on. Because if you weren’t told, if you weren’t raised in your religion, how do you know about another one?

31:03 So did that, and then I came full circle to realize, yes, this is my belief, and this is what I’m going to believe. And so for me, it was a lot of really creating the relationship between God and I. And I literally look at Jesus as my friend when I was in sales. I literally would envision Jesus in the interseed as I’m driving all over Eastern Iowa, where I’m from, and start to really create that close friendship with my faith. And then for Christians, you have the Bible then to reinforce what you’re supposed to be learning. And so for me, I spend so much time learning Scripture and learning the Bible that then reinforces my faith, and for me then to live it just becomes really powerful. And because that I have set that, it is really how my whole life is informed.

31:45 It’s through that filter, and without saying obviously I’m not perfect and I do things wrong and I drink beer on the weekends and I boat and I cuss and I do all that stuff, and I feel guilty. But you still are that person. But it also, for me, is there’s a purpose for me. There’s a higher being watching out for me. There is a need for me to step out in faith in things that I don’t personally think I can do, but God is telling me that I can. The social media thing was one thing where I felt really strongly like you just need to do this, and I didn’t know why, and so I’ve just done it.

32:22 Even job roles that I’ve been handed, like some people call it imposter syndrome, maybe it is imposter syndrome, but you really need something to back you while you’re in that imposter syndrome that you know is faithful and for you, and that will not let you fail, and so that’s how I’ve always overcome any sort of imposter syndrome. Is just that faith, and so I think your question about how it’s affected me or how I’ve utilized it’s who I am, and it’s in every decision I make, and every morning I reread scripture and relearn and go through deserts, and then it’s a real journey, and you’re never going to know it all. I think that’s the other thing: is you’re never going to know it all. You’re never going to get a solid answer either. So that’s why it’s faith.

33:03 So I hope that didn’t ramble too much.

33:13 Patrick Coyle: No, that was phenomenal, and I think the humility to know that you can’t know it all. And it’s interesting you talking about the imposter syndrome because I think the difference for any of us, whether we can do something or can’t do it, is when we’re given that torch and we feel that imposter syndrome. Do we run with it? Do we fumble it? And you fumble it. Okay, that was imposter syndrome. And if you run with it, it’s not because we can all do difficult, impossible things every day, and that faith keeps us going. Like you talked about, and you said you coming through some personal values. What do they teach you about carrying that responsibility for other people?

33:50 Suzanne Morgan: For me, when I was in the deepest and depths of my depression and trying to climb out of that, believing in a God that loved me enough to pull me out of that, I feel really responsible that I want to make sure that if Christianity is what people choose their faith to be, that I help them know how to use that in a practical sense. I’ve never been the person that was always perfect, was always this, but I’ve been more of a fighter. And how do you use that fighting philosophy and that kind of ferocity to be successful in business and and use your faith with it too.

34:24 And so I feel like if people understand you can have a strong faith and be great in business and do all of this, that’s my goal is just to help people use their faith in business because it makes business better, right? Instead of the people that have no check on greed or whatever, if you have a faith and a responsibility to humankind, I think you’re going to make business better. And so I feel really strongly about helping people find that voice and helping people find that path for them, their faith, whatever their faith may be.

34:59 Patrick Coyle: And your stories and what you’ve been through in climbing out those personal valleys, and how your faith has done that, and how you’ve taken the torch and run with it over and over again makes me very curious to see what that next torch and how big that is that you’re going to be given, because you know what happens when you ask for it.

35:19 Suzanne Morgan: You get more. And I’ve often prayed, God, seriously, I can’t take on anymore. Don’t get me anymore, please. And so then it gives you the next job, right? The next role, the next quest, whatever that is. But I think in general, I just want to help people their faith in life and not have it just a Sunday thing, right? How do you use your faith when your boss is a jerk. How do you use faith when you’re mad at your coworker and they screwed you over? Like, how do you do that, and how do you become a better person through it? That’s what my faith has done for me.

35:54 Patrick Coyle: I am so grateful for you being a guest on our podcast and sharing your experience and your faith with the audience, and I know you’ve inspired me, and I think you’re going to inspire a lot of other people that are going to listen to this. And so I just want to say thank you for being here.

36:15 Suzanne Morgan: Of course, thank you. It’s been fun. Thank you.

36:19 Patrick Coyle: Great, and I look forward to all the amazing work you’re going to continue to do, and a reminder to our audience that Patients + Profitability are not competing priorities; they rise and fall together. They are the same thing, so it’s time we start talking about them together. Thanks so much for your time, Suzanne.

36:36 Suzanne Morgan: Thank you, Patrick. Have a great day.